甲氨蝶呤联合艾拉莫德治疗难治性类风湿关节炎的效果.docVIP

甲氨蝶呤联合艾拉莫德治疗难治性类风湿关节炎的效果 　　[摘要] 目的 观察甲氨蝶呤（MTX）联合艾拉莫德治疗难治性类风湿关节炎的效果。 方法 60例难治性类风湿关节炎患者均来自2013年12月～2014年2月南京医科大学附属淮安第一医院风湿免疫科，将其随机分为实验组和对照组，各30例。实验组给予艾拉莫德（50 mg/d）联合MTX（每周15 mg）治疗，对照组仅以相同方法予MTX治疗，疗程16周。治疗前、治疗后16周评估记录患者疾病活动性评分（DAS28），并采血以酶联免疫吸附测定法检测肿瘤坏死因子α（TNF-α）、血管内皮生长因子（VEGF）水平。 结果 两组治疗前DAS28评分比较差异无统计学意义[实验组：（5.97±1.62）分；对照组：（6.40±1.90）分；P 0.05]，两组治疗16周后DAS28评分[实验组：（3.02±1.24）分；对照组：（5.65±1.86）分]均较治疗前显著下降，差异均有统计学意义（P 0.05]，两组治疗16周后血清TNF-α浓度[实验组：（230.42±67.23）pg/mL；对照组：（309.65±95.59）pg/mL]均较治疗前显著下降，差异均有统计学意义（P 0.05]，两组治疗16周后血清VEGF浓度[实验组：（818.89±178.78）pg/mL；对照组：（1000.21±245.87）pg/mL]均较治疗前显著下降，差异均有统计学意义（P 中国论文网 /6/view-7215483.htm 　　[关键词] 艾拉莫德；甲氨蝶呤；难治性类风湿关节炎；肿瘤坏死因子-α；血管内皮生长因子 　　[中图分类号] R593.22 [文献标识码] A [文章编号] 1673-7210（2016）01（c）-0137-05 　　Effect of Methotrexate combined with Iguratimod in the treatment of patients with refractory rheumatoid arthritis 　　MENG Deqian PAN Wenyou▲ LI Ju LI Hui LI Fang LIU Shanshan LI Yongsheng CHENG Yuling 　　Department of Rheumatology， Huai’an First People’s Hospital， Nanjing Medical University， Jiangsu Province， Huai’an 223300， China 　　[Abstract] Objective To observe the effect of Methotrexate （MTX） combined with Iguratimod in the treatment of patients with refractory rheumatoid arthritis. Methods Sixty patients with refractory rheumatoid arthritis were all coming from Department of Rheumatology， Huai’an First People’s Hospital， Nanjing Medical University from December 2013 to February 2014， they were randomly divided into experimental group and control group， with 30 cases in each group. The experimental group was given Iguratimod （50 mg/d） and MTX （15 mg one week）， the control group was given the same dose of MTX， the course was 16 weeks. Before treatment and after treatment for 16 weeks， the disease activity score 28 （DAS28） was evaluated and recorded. And serum samples were retrieved， levels of tumor necrosis factor alpha （TNF-α） and vascular endothelial growth factor （VEGF） were quantified by enzyme-linked immunosorbent assay